Stocks · News reference
Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applicationsHyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Hyperfine (NASDAQ:HYPR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
Filed: 2026-10-08 AccNo: 0001193125-26-417437 Size: 9 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Hyperfine (NASDAQ:HYPR) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000 million-$22.000 million vs $20.163 million estimate.